Smith Group Asset Management LLC Takes Position in Bristol Myers Squibb Company $BMY

Smith Group Asset Management LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,850 shares of the biopharmaceutical company’s stock, valued at approximately $840,000.

A number of other hedge funds have also recently bought and sold shares of BMY. Brighton Jones LLC boosted its holdings in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares in the last quarter. United Bank lifted its position in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $405,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $63.65 on Wednesday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $64.96. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market capitalization of $129.97 billion, a price-to-earnings ratio of 17.88, a P/E/G ratio of 0.18 and a beta of 0.23. The stock’s fifty day simple moving average is $57.70 and its 200-day simple moving average is $58.17.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Guggenheim restated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, Bank of America reduced their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.